KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Cash from Operations (2016 - 2025)

Regeneron Pharmaceuticals (REGN) has 17 years of Cash from Operations data on record, last reported at 1170700000.0 in Q4 2025.

  • For Q4 2025, Cash from Operations fell 7.29% year-over-year to 1170700000.0; the TTM value through Dec 2025 reached 4978900000.0, up 12.63%, while the annual FY2025 figure was 4978900000.0, 12.63% up from the prior year.
  • Cash from Operations reached 1170700000.0 in Q4 2025 per REGN's latest filing, down from 1618700000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 2101700000.0 in Q1 2022 and bottomed at 354000000.0 in Q2 2024.
  • Average Cash from Operations over 5 years is 1157458823.53, with a median of 1144400000.0 recorded in 2025.
  • Peak YoY movement for Cash from Operations: plummeted 65.38% in 2024, then soared 223.28% in 2025.
  • A 5-year view of Cash from Operations shows it stood at 668500000.0 in 2021, then soared by 157.28% to 1719900000.0 in 2022, then plummeted by 36.64% to 1089700000.0 in 2023, then grew by 15.89% to 1262800000.0 in 2024, then dropped by 7.29% to 1170700000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Operations were 1170700000.0 in Q4 2025, 1618700000.0 in Q3 2025, and 1144400000.0 in Q2 2025.